Bausch + Lomb Corp (BLCO : TSX)
Common Stock
$22.96
CAD
+0.07 (0.31%)
Last updated: 2026-07-13
BLCO
Bausch + Lomb Corp
WealthAwesomePerformance
1 Day
+0.31%
1 Week
-5.71%
1 Month
+8.82%
YTD
+0.75%
Key Statistics
Market Cap
$8.16B
52W High
$25.70
52W Low
$18.24
P/E Ratio
-
50 Day MA
$22.05
200 Day MA
$22.46
Beta
0.56
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/13/2026 | $23.10 | $23.23 | $22.83 | $22.96 | $22.96 | 2,154 |
| 7/10/2026 | $23.64 | $23.64 | $22.60 | $22.89 | $22.89 | 3,560 |
| 7/9/2026 | $23.57 | $23.72 | $23.44 | $23.72 | $23.72 | 1,506 |
| 7/8/2026 | $23.87 | $23.87 | $23.25 | $23.25 | $23.25 | 2,203 |
| 7/7/2026 | $24.38 | $24.60 | $24.31 | $24.31 | $24.31 | 703 |
| 7/6/2026 | $24.03 | $24.35 | $23.86 | $24.35 | $24.35 | 2,601 |
| 7/3/2026 | $24.35 | $25.10 | $24.19 | $24.55 | $24.55 | 5,980 |
| 7/2/2026 | $23.73 | $24.37 | $23.73 | $24.32 | $24.32 | 3,511 |
| 6/30/2026 | $22.90 | $23.63 | $22.90 | $23.46 | $23.46 | 3,000 |
| 6/29/2026 | $23.17 | $23.50 | $23.17 | $23.50 | $23.50 | 713 |
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.6% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.92
-17.6% Upside
Current Price
C$22.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
31.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$23.19
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$23.04 | C$20.56 – C$25.81 |
| 60 trading days | C$23.11 | C$19.68 – C$27.14 |
| 90 trading days | C$23.19 | C$19.05 – C$28.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Financials
- Revenue (TTM)
- $5.21B
- EBITDA
- $724.00M
- Profit Margin
- -4.21%
- ROE (TTM)
- -3.28%
- EPS (Diluted)
- -0.88
- Book Value
- 25.36
Classification
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Group
- Health Care Equipment & Services
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About BLCO
Articles Featuring BLCO.TO
Latest articles and analysis covering BLCO.TO
Why Bausch + Lomb Corp stock is tanking today
Bausch + Lomb Corp's stock faced a downturn of 1.13% after the company announced that its experimental glaucoma treatment did not meet its primary endpoint in clinical trials, leading to a halt in its development. This news has raised concerns about the company's future growth prospects.
What's Going On With Bausch + Lomb Corp Stock Tuesday?
Bausch + Lomb Corp's stock has shown mixed performance this week, closing at C$22.96 with a slight daily gain amidst a broader sector decline. Recent product updates and market reports are influencing investor sentiment as the company navigates its path in the competitive healthcare landscape.
Why Bausch + Lomb Corp stock is sliding today
Bausch + Lomb Corp's stock plummeted by 4.09% following disappointing Phase 2 trial results for its glaucoma treatment, prompting investors to reassess the company's strategic direction and pipeline potential.
Why Bausch + Lomb Corp stock is sliding today
Bausch + Lomb Corp's stock is under pressure today, reflecting broader concerns about its financial performance and market forecasts. As it navigates a challenging environment, investors may want to reassess their positions.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp (BLCO.TO) shares rose by 3.67% in the last trading session, closing at CA$24.32. This increase comes on the heels of new survey data highlighting the significant impact of dry eye treatments on patients' quality of life, which may bolster the company's market position in the eye health sector.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp (BLCO.TO) experienced a 2.13% rise in its stock price, closing at CA$23.05. This uptick may indicate a shift in investor confidence, despite the company's recent struggles with earnings.
Bausch + Lomb Corp (BLCO.TO) Rises 7% This Week — What’s Driving the Momentum?
Bausch + Lomb Corp (BLCO.TO) has gained 7% this week, reflecting investor optimism amid ongoing profitability challenges. Here's what you should know.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp's stock rose by 2.66% in the latest trading session, reflecting positive investor sentiment amid ongoing developments in the optical health industry.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp's stock rose 2.04% in the last session, driven by strategic advancements and partnerships aimed at enhancing its ophthalmic product offerings.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp's stock rose 3.06% in the last trading session, closing at CA$21.24, fueled by strategic developments in the ophthalmic sector.
Why Bausch + Lomb Corp stock is sliding today
Bausch + Lomb Corp's stock fell by 2.04% today, closing at CA$20.61. Investors are reacting to the company's financial metrics and recent strategic investments, highlighting concerns over its profitability and market position.
Why Bausch + Lomb Corp stock is rising today
Bausch + Lomb Corp's stock surged by 3.22% in the last trading session, buoyed by strong financial results and an optimistic outlook for the year ahead.
Bausch + Lomb Corp. (BLCO.TO) Faces Pressure After Last Session's Decline
Bausch + Lomb Corp. faced a significant decline in share price during the last session, with no recent news to clarify the downturn.
Why Bausch + Lomb Corp stock is sliding today
Bausch + Lomb Corp's stock fell 2.50% today, closing at CA$21.10. This decline comes despite the company's recent product launch aimed at addressing dry eye symptoms, raising concerns about its market performance.
7 Best Healthcare Stocks In Canada to Buy In July 2026
A decent number of sources place Canada's healthcare system among the top ten in the world. Most of the 1,200 hospitals in Canada are publicly funded, and only a tiny number are purely for-profit. With this level of public funding and ownership, the healthcare industry landscape (from an investment
![7 Best Healthcare Stocks In Canada to Buy In [currentmonthyearfull]](https://lhajohzwizrsjmumhpjg.supabase.co/storage/v1/object/public/wealth-awesome/site-media/best-healthcare-stocks-in-canada_Bausch-Lomb-Logo-1024x532.png){kind=logo}